NASH - Nonalcoholic Steatohepatitis, Nonalcoholic Steatohepatitis
Conditions
Keywords
Tc99m-tilmanocept, Tilmanocept, NASH, Nonalcoholic Steatohepatitis
Brief summary
This is a prospective, open-label, multicenter, safety, comparative study of IV administered Tc99m-tilmanocept and unfiltered Tc99m sulfur colloid in the detection of and assessment of three dimensional tessellation localization to the liver in subjects with and without moderate to severe nonalcoholic steatohepatitis (NASH) by planar and SPECT/CT imaging. This study is designed to evaluate the safety and tolerability of Tc99m-tilmanocept in subjects with NASH.
Interventions
DRUGTc 99M Sulfur Colloid
Sulfur colloid is a radiotracer that is indicated for imaging areas of functional reticuloendothelial cells in the liver, spleen, and bone marrow.
Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.
Sponsors
Navidea Biopharmaceuticals
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* ALL SUBJECTS: 1. The subject has provided written informed consent with HIPAA (Health Information Portability and Accountability Act) authorization before the initiation of any study-related procedures. 2. The subject is ≥18 years of age at the time of consent. 3. The subject has a body mass index (BMI) between 18 and 45. CONTROL SUBJECTS: 4. The subject is deemed to be clinically free of any infectious/inflammatory disease(s) for at least 4 weeks prior to the consent date. 5. The subject has not taken any antibiotics for at least 4 weeks prior to the consent date. NASH SUBJECTS: 4\. The subject has biopsy-confirmed NASH within 12 months prior to enrollment. 5. The subject has a NAFLD Activity Score (NAS) of ≥ 4, with a score of at least 1 for each steatosis, lobular inflammation, and hepatocyte ballooning. 6\. The subject has fibrosis staging of F3-F4.
Exclusion criteria
* ALL SUBJECTS: 1. The subject is pregnant or lactating. 2. The subject size or weight is not compatible with imaging per the investigator. 3. The subject has received radiation therapy or chemotherapy or has a previous diagnosis of cancer other than basal cell carcinoma. 4. The subject has renal insufficiency as demonstrated by a GFR of \< 60 mL/min. 5. The subject has a chronic or persistent infection or has any condition that would, in the opinion of the examining physician, preclude their participation. 6. The subject has a known allergy to or has had an adverse reaction to dextran exposure. 7. The subject has received an investigational product within 30 days prior to the Tc 99m sulfur colloid administration. 8. The subject has received any radiopharmaceutical within 7 days prior to the administration of Tc 99m sulfur colloid. 9. The subject is HIV positive. 10. The subject has a history of alcohol abuse or currently consumes alcohol in excess of 3 drinks/day for men or 2 drinks/day for women. 11. The subject has hepatitis B or C. CONTROL SUBJECTS: 12. The subject has hepatic insufficiency as demonstrated by ALT (alanine aminotransferase \[SGPT\]) or AST (aspartate aminotransferase \[SGOT\]) greater than two times the upper limit of normal (ULN). 13. The subject has been diagnosed with NASH, NAFLD, or other chronic liver disease. 14. The subject has been diagnosed with metabolic syndrome or Type I or II diabetes. NASH SUBJECTS: 12\. The subject has any chronic liver disease aside from NASH/NAFLD. 13\. The subject has uncontrolled diabetes as indicated by an A1c \>9% within the 3 months prior to enrollment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Adverse Drug Reaction | 5 days after Tc 99m tilmanocept injection | Proportion of subjects experiencing noxious pharmacologic activity/an Adverse Drug Reaction (ADR). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Localization of Tc 99m tilmanocept | 5 days after Tc 99m tilmanocept injection | Determine the three dimensional tessellation localization of Tc 99m tilmanocept by planar and SPECT/CT imaging in subjects with NASH and asymptomatic controls. |
| Localization of Tc 99m sulfur colloid | 5 days after Tc 99m tilmanocept injection | Determine the three dimensional tessellation localization of unfiltered Tc 99m sulfur colloid by planar and SPECT/CT imaging in subjects with NASH and asymptomatic controls. |
| Localization Distribution Comparison | 5 days after Tc 99m tilmanocept injection | Comparison of liver localization distribution tessellation pattern intensities between Tc 99m tilmanocept and unfiltered Tc 99m sulfur colloid. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Tc 99m tilmanocept Localization Distribution of SPECT/CT vs Elastography | 5 days after Tc 99m tilmanocept injection | Concordance of intrahepatic localization tessellation discrimination of Tc 99m tilmanocept (intrahepatic disease heterogeneity) by SPECT/CT imaging and elastography. |
| Tc 99m sulfur colloid Localization Distribution of SPECT/CT vs Elastography | 5 days after Tc 99m tilmanocept injection | Concordance of intrahepatic localization tessellation discrimination of Tc 99m sulfur colloid (intrahepatic disease heterogeneity) by SPECT/CT imaging and elastography. |
Countries
United States
Outcome results
None listed